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Borderline ovarian tumor and future fertilityMaintenance of future fertility in women with malignant
diseases, especially cancers occurring in the reproductive
organs, was often impossible before.1 However, a recent trend
among women of reproductive age has been toward delayed
pregnancy,2 so more and more of these women may request
the preservation of their future fertility when they are diag-
nosed with a malignancy.3 Therefore, fertility preservation
for these women is an important issue. Fortunately, with
significantly advanced anti-neoplastic treatments, for example,
the use of the multi-modality therapeutic strategy and
conservative surgery (organ-preserving surgery), the manage-
ment of cancers of the female reproductive organs, including
early-stage endometrial cancers, cervical cancers and even
ovarian cancers, has become possible.4
Since organ-preserving treatment can be used in the
management of early-stage cancers of the reproductive organs
in women, there is no doubt that less invasive types of tumors,
for example, borderline ovarian tumor, are also good candi-
dates for conservative treatment with a high possibility of
preserving the ovary. Cystectomy may have a better chance of
preserving a woman’s fertility than adnexectomy (oophorec-
tomy), because of the removal of less ovarian tissue. However,
borderline ovarian tumor cannot be considered completely
benign, and although rare, there is a consistent percentage of
tumor recurrence, which may possibly result in tumor-related
death. The 5-year survival for Stage-I and Stage IIeIII
borderline ovarian tumors is about 95e97% and 65e87%,
respectively.5 The 10-year survival for even Stage I borderline
ovarian tumors is reported to range from 70e95%.5 Therefore,
the question “how should these patients be treated?” is raised.
In this issue, Tsai et al.6 studied 61 women with borderline
ovarian tumor, and found that no patients who were treated
with radical surgery had recurrence during the mean follow-up
period of 56 months. In contrast, more than 20% of patients
who underwent fertility-sparing surgery developed tumor
recurrence within 10e56 months, with a median of 25.1
months.
Tsai et al.6 further analyzed these 7 patients with recurrent
diseases and found that up to two-thirds (n ¼ 5) were treated
with cystectomy only. Therefore, the authors concluded that
unilateral salpingo-oophorectomy (USO) must be considered
as the first choice. In fact, this finding is not brand new, since1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.04.001Dr. Tinelli also suggested that when borderline ovarian tumors
are identified at surgery by intraoperative histology, the rec-
ommended conservative treatment should be laparoscopic
salpingo-oophorectomy.7
Although Dr. Tsai’s report demonstrated a relatively clear
conclusion regarding the management of borderline ovarian
tumors in women, there are still a lot of questions. For
example, it is interesting to find the authors concluding that
fertility-sparing surgery is an acceptable and safe option for
women with borderline ovarian tumors who wish to preserve
fertility. It is not rational to reach such a conclusion if none had
recurrence in the radical surgery group (fertility-destructive
surgery), compared with more than 20% of patients in the
fertility-sparing surgery group. Fortunately, all patients with
recurrence were free of the tumor because recurrent tumors can
be eliminated by the secondary surgery. This finding might
support the authors’ above-mentioned conclusion. In fact,
Lenhard et al.8 showed similar findings e that 5- and 10-year
survival rates of women treated with fertility-sparing surgery
(n ¼ 19) were 100%, and thus not worse than those of patients
undergoing radical operation (5- and 10-year survival, 95.1
and 90.1%).
Furthermore, among 7 women with recurrent disease, 2
developed invasive carcinomas. One woman underwent cys-
tectomy and the other was treated with USO. In fact, it is not
appropriate to include these 2 patients e any woman with
benign tumors undergoing conservative treatment may face
the possibility of malignancy of the same organ in the future.
It is not acceptable that a patient with a diagnosis of relatively
benign lesions should be treated with complete resection of
the entire organ to minimize recurrence. This concept might
be similar to the prophylactic oophorectomy or mastectomy in
BRCA1 carriers, which is still debated.9 Therefore, USO
might not be better than cystectomy in the management of
borderline ovarian tumor because the risk of future malig-
nancy of the residual organs may be similar in both groups, if
we consider the possibility of future pregnancy. In contrast,
after excluding the 2 invasive tumors, the remaining 5
recurrent cases showed 3 (60%) in the same site (the original
site of the borderline ovarian tumor) and 2 (40%) in the
opposite site (supporting the new development of a borderline
ovarian tumor), suggesting that the remaining ovarian tissuehinese Medical Association. All rights reserved.
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same ovary might be derived from the de novo development of
the new lesion, but it is more possible that some borderline
ovarian tumor cells were not removed completely during the
first operation. In fact, the 3 patients with recurrence of the
ipsilateral ovary had rupture during the first operation.
Although we do not know what happened to these 3 patients, it
is highly suspected that it may be really difficult or even
impossible to perform complete resection of ovarian borderline
tumors in these patients who wish to preserve their ovary.
Finally, concern about the overuse of lymphadenectomy
has always existed and is still a subject of controversy. Almost
all patients (96.7%) in the radical surgery group and half of the
patients (48.4%) in the fertility-sparing surgery group in
Tsai’s report underwent lymphadenectomy.5 Neither univar-
iate analysis for disease-free survival nor multivariate analysis
showed any significant value for lymphadenectomy in the
management of women with borderline ovarian tumors. In
fact, there are a handful of papers showing the limited or lack
of value of lymphandenectomy for early-stage borderline
ovarian tumors,3,8,10 although this procedure is still often
performed during the complete staging surgery.
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